@JoeChangMD

Endowed Texas 4000 Distinguished Professor and Director, Stereotactic Ablative Radiotherapy Program, MD Anderson Cancer Center

 Houston,TX
faculty.mdanderson.org/joe_chang/
Joined July 2015
  • Tweets618
  • Following358
  • Followers3K
186Media
Yes, it works in pancreatic cancer.
Shankar Siva
@_ShankarSivaOct 23
🚨📣 big news at #ESMO26: 🧵1/MASTERPLAN RCT shows adding SABR to perioperative chemotherapy for high-risk localized #pancreatic cancer ⬆️⬆️ median overall survival to 22.0 months vs 14.0 months (HR 0.45). #PancreaticCancer #RadOnc @TROGfightcancer in press @TheLancetOncol - thelancet.com/journals/lanon…
5
15
1,013
Alternatively, Pope Leo could have stereotactic ablative radiotherapy if his tumor is small, peripherally located, medium/high risk or refusal for lobectomy. 2025 ASTRO presentation comparing SABR vs VATS showed no inferiority in overall survival at 10 years. Manuscript will be published soon.
Stephen V Liu, MD
@StephenVLiuOct 13
Pope Leo XIV has been diagnosed with lung adenocarcinoma. While we had hoped for a different diagnosis, the fact that he was able to undergo a lobectomy is encouraging. Surgery is generally pursued when lung cancer appears localized and potentially curable. Final pathology will help determine prognosis and whether additional treatment is needed. Wishing the Holy Father a smooth and speedy recovery. lombardi.georgetown.edu/lomb…
2
10
67
4,135
In appropriate patients, appropriate times, appropriate locations, radiotherapy will make significant impact to improve patient outcomes.
Eric K. Singhi, MD@lungoncdocOct 14
When I say ‘just a little radiation’ and he knows exactly where this is going… @JoeChangMD #DCLung26 🤣
1
2
19
1,255
MDT management is crucial for stage III NSCLC. For sure, we need more well-design clinical trials to better define the role of radiotherapy vs surgery in stage III NSCLC in the era of immunotherapy and molecular targeted treatment.
Eric K. Singhi, MD@lungoncdocOct 10
#DCLung26 Debate Starts NOW!! LAURA v NeoADAURA @JSabari @JuliaRotow @StephenVLiu @Joshua_Reuss
7
753
As we confront the world’s number-one cancer killer, we need novel biological insights and cutting-edge technologies to improve clinical outcomes for patients with lung cancer. The great news is that lung cancer survival has nearly doubled since I joined the field of thoracic radiation oncology 24 years ago.
Eric K. Singhi, MD@lungoncdocOct 10
Best part of the #DCLung26 lung conference? Difficult case discussions! Here’s an early stage NSCLC case we discussed! @StephenVLiu @Joshua_Reuss @ErinGillaspie @JoeChangMD
3
4
32
1,988
Join us in Washington, DC tomorrow, Saturday, October 10 for #DCLung26 - a 1-day, comprehensive, @IASLC endorsed, multidisciplinary, discussion-based lung cancer CME update! On-site registration available and join us afterwards for our inaugural gala! medstarhealth.org/dclung
11
2
15
2,898
Joe Y Chang retweeted
OncoDaily RT
@OncoDailyRTSep 30
I-SABR Phase II Study Shows Improved Overall Survival With Immunotherapy Added to SABR in Early-Stage NSCLC - Joe Y Chang @JoeChangMD oncodaily.com/voices/joe-y-c…
1
2
142
Joe Y Chang retweeted
Kate Sears
@OpenMedKateSep 30
2/ @OncoAlert @JoeChangMD on nivolumab following SBRT in early stage NSCLC (I-SABR): xitter.cf/OncoAlert/status/21045…
OncoAlert
@OncoAlertSep 28
In Collaboration with our partners at ASTRO we continue our coverage of #ASTRO26 🚨 SIX-YEAR OVERALL SURVIVAL OF NIVOLUMAB FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY IN EARLY-STAGE NON-SMALL CELL LUNG CANCER: RANDOMIZED I-SABR TRIAL Presented by Dr. Joe Chang🇺🇸 @JoeChangMD, @StevenLin_MDPhD, @StephenChunMD, @MehmetAltanMD, @aileenbchen, @pamsharmamdphd, @JHeymach This randomized phase II trial evaluated SABR ☢️ alone versus SABR plus four doses of nivolumab (I-SABR) in 141 patients with node-negative, early-stage or isolated recurrent #NSCLC 🫁 . ➡️ After nearly 6 years of follow-up, I-SABR significantly improved overall survival (70% vs. 56%) and event-free survival (53% vs. 32%), with manageable toxicity and low rates of severe nivolumab-related adverse events. ✅️ Findings support combining SABR with immunotherapy in appropriately selected patients. Social Champtions @DrewMoghanaki, @themednet, @nadinehousri, @IAbuGheidaMD, @lauren_henke, @TugceKutukMD, @ARRO_org, @sarthakshah097, @P_Shams_, @CJTsaiMDPhD, @TylerSbrt, @barrosonco, @AlexisNarvaezMD, @OncoAlert, @CancerNetwrk , @ASTRO_org , @PRJeffWhite OncoAlert RT Faculty @MKnoll_MD @HenningWillers @fumikochino @_ShankarSiva @PercyLeeMD @Icro_Meattini @ErinGillespieMD @seanmmcbride @NiuSanford @to_be_elizabeth
1
3
5
789
Thank you so much for the great summary and wonderful picture for our I-SABR study.
Dr Najeed Aadil@daakhsaabSep 27
SBRT with immunotherapy significantly boosts long-term cancer survival. The 6-year overall survival reached 69% with the combined approach, compared to 55% with radiation alone. This major improvement is driven by a powerful, sustained immune response! #ASTRO26
1
6
868
I am so glad that Bruce received this well deserved recognition. I am still missing him whenever I go to my office in MDACC. We used to be the neighbors for our office.
Prajnan Das@PrajnanDasMDSep 29
Congrats to @UTMDAnderson Professor Emeritus Dr. Bruce Minsky for being awarded the @ASTRO_org Gold Medal! #ASTRO26
14
1,139
Thanks for the ASTRO photographer for this nice photo.
ASTRO
@ASTRO_orgSep 27
The highly anticipated #ASTRO26 Clinical Trials Session showcased important new evidence and emerging advances across radiation medicine, highlighting findings with meaningful implications for clinical practice. Start planning your schedule for Day 3: bit.ly/4rzbxYt
12
754
I am honored to see that I made #ASTRO26 @ASTRO_org daily news.
Mayo Clinic Radiation Oncology@MayoRadOncSep 28
Look who made the #ASTRO26 @ASTRO_org’s Daily News! @n_laack @PDBrownOnc
2
20
1,534
For low and intermediate localized prostate cancer, which TX is better, surgery vs SBRT? Phase III randomized PACE-A showed similar biological or clinical failure rate and OS. Side effects seem favorable in SBRT. Overall, patients have two very effective TX options.
1
4
8
577
What is the optimal RT for brain mets in small cell lung cancer. NRG -CC009 compared SRS vs HA-WBRT. Although SRS doesn’t improve neurocognative function but it improves OS. SRS will be an option (preferred?) for brain mets in small cell lung cancer.
1
14
2
18
1,379
Looking forward to seeing you there.
UT MD Anderson
@UTMDAndersonSep 28
Replying to @UTMDAnderson @crweil @OmranSaifi @suwusan
Transformative techniques are changing thoracic cancer care. Join our experts at 4 p.m. ET to learn the latest. More about thoracic radiation oncology at UT MD Anderson: spr.ly/6014BGojaj @JoeChangMD (4/4) #EndCancer

Thoracic Radiation Oncology

mdanderson.org
3
535
Joe Y Chang retweeted
OncoAlert
@OncoAlertSep 28
In Collaboration with our partners at ASTRO we continue our coverage of #ASTRO26 🚨 SIX-YEAR OVERALL SURVIVAL OF NIVOLUMAB FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY IN EARLY-STAGE NON-SMALL CELL LUNG CANCER: RANDOMIZED I-SABR TRIAL Presented by Dr. Joe Chang🇺🇸 @JoeChangMD, @StevenLin_MDPhD, @StephenChunMD, @MehmetAltanMD, @aileenbchen, @pamsharmamdphd, @JHeymach This randomized phase II trial evaluated SABR ☢️ alone versus SABR plus four doses of nivolumab (I-SABR) in 141 patients with node-negative, early-stage or isolated recurrent #NSCLC 🫁 . ➡️ After nearly 6 years of follow-up, I-SABR significantly improved overall survival (70% vs. 56%) and event-free survival (53% vs. 32%), with manageable toxicity and low rates of severe nivolumab-related adverse events. ✅️ Findings support combining SABR with immunotherapy in appropriately selected patients. Social Champtions @DrewMoghanaki, @themednet, @nadinehousri, @IAbuGheidaMD, @lauren_henke, @TugceKutukMD, @ARRO_org, @sarthakshah097, @P_Shams_, @CJTsaiMDPhD, @TylerSbrt, @barrosonco, @AlexisNarvaezMD, @OncoAlert, @CancerNetwrk , @ASTRO_org , @PRJeffWhite OncoAlert RT Faculty @MKnoll_MD @HenningWillers @fumikochino @_ShankarSiva @PercyLeeMD @Icro_Meattini @ErinGillespieMD @seanmmcbride @NiuSanford @to_be_elizabeth
2
28
1
37
3,118
Joe Y Chang retweeted
ASTRO
@ASTRO_orgSep 27
The highly anticipated #ASTRO26 Clinical Trials Session showcased important new evidence and emerging advances across radiation medicine, highlighting findings with meaningful implications for clinical practice. Start planning your schedule for Day 3: bit.ly/4rzbxYt
4
1
7
1,722
Combined immunotherapy with radiotherapy is exciting but also challenging. Biology-based clinical trial design and optimization is crucial.
Moffitt Cancer Center
@MoffittNewsSep 27
LIVE from #ASTRO26: Joe Chang, MD, (@JoeChangMD) of @UTMDAnderson discusses the randomized I-SABR trial, which looks at adding four doses of nivolumab to SABR to improve 6-year overall survival (70% vs. 56%) and event-free survival (53% vs. 32%) in early-stage, node-negative NSCLC. The treatment had generally manageable toxicity, supporting further study of I-SABR and optimal immunotherapy sequencing. #MoffittASTRO26
2
10
922
I am pleased to share the results of our phase II randomized I-SABR study @ASTRO_org 2026 which demonstrate improved overall survival (OS) when adding four doses of immunotherapy to SABR in early-stage NSCLC. These exciting findings are associated with the persistent activation of cytotoxic T cells for up to 6.5 years. Further optimization of I-SABR approaches will guide future research and clinical practice.
UT MD Anderson
@UTMDAndersonSep 27
Replying to @UTMDAnderson
Dr. Joe Chang shared six-year data from the Phase 2 I-SABR trial. He also shared that patients who received both nivolumab and SBRT treatment showed increased activity of cancer-targeting CD8+ T cells: spr.ly/6018BGWA4O (2/2) #ASTRO26 #EndCancer
Photo of Dr. Joe Chang standing on a stage and giving a presentation with a screen of slides.

ALT Photo of Dr. Joe Chang standing on a stage and giving a presentation with a screen of slides.

4
22
2
81
5,537
Load more